Aquestive Therapeutics: Anaphylm Will Probably Survive This Regulatory Hurdle [Seeking Alpha]
Aquestive Therapeutics, Inc. (AQST)
Last aquestive therapeutics, inc. earnings: 3/11 04:30 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.aquestive.com/investor-relations
Company Research
Source: Seeking Alpha
The FDA's communication is so far procedural, not substantive or a definitive rejection; issues are more likely related to manufacturing or packaging rather than efficacy or safety. AQST's $120 million, at a current burn rate of $5 million a month, shall provide sufficient runway for the company to address this setback. I remain cautiously optimistic on AQST's eventual approval prospects but acknowledge higher risk and patience are now required. edb3_16/iStock via Getty Images Back in October 2025, I shared with my followers this personal story and investment analysis on Aquestive Therapeutics ( AQST ). Based upon the information that I had then, I rated the stock a cautious BUY based This article was written by Analyst's Disclosure: I/we have a beneficial long position in the shares of AQST either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from S
Show less
Read more
Impact Snapshot
Event Time:
AQST
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AQST alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AQST alerts
High impacting Aquestive Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
AQST
News
- Jim Cramer: The whole Aquestive situation seems very ambiguous [CNBC]CNBC
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc. - AQSTPR Newswire
- INVESTOR ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Aquestive TherapeuticsGlobeNewswire
- INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aquestive Therapeutics, Inc. - AQSTGlobeNewswire
- Assessing Aquestive Therapeutics (AQST) Valuation After FDA Flags Anaphylm Application Deficiencies [Yahoo! Finance]Yahoo! Finance
AQST
Earnings
- 11/5/25 - Miss
AQST
Sec Filings
- 1/9/26 - Form 8-K
- 12/5/25 - Form 4
- 12/4/25 - Form 4
- AQST's page on the SEC website